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Introduction
Atrial fibrillation constitutes a major risk factor for stroke and death.
1- 3 The risk of stroke in atrial fibrillation is currently estimated by clinical risk factors, e.g. the CHA 2 DS 2 VASc score. 4 The development of stroke can be prevented by oral anticoagulation. However, anticoagulant treatment is also associated with a risk of major bleeding, which can be predicted with the HASBLED clinical score. 5 The indication for stroke prevention by oral anticoagulation is based on balancing the reduction of stroke versus the increase in bleeding in relation to type of oral anticoagulation and patient characteristics. 6 Unfortunately the risk factors for stroke and major bleeding are to a large extent overlapping. Consequently there is a need for new and independent risk indicators for stroke, bleeding and mortality, in patients with atrial fibrillation.
Recently cardiac troponin, a marker of myocardial cell damage, was identified as an independent biomarker of the risk of stroke, mortality, and bleeding in patients with atrial fibrillation. [7] [8] [9] NT-proBNP, a marker of cardiac dysfunction was also recently shown to contribute independent information on the risk of stroke and mortality in patients with atrial fibrillation. 9, 10 Markers of renal dysfunction, e.g. creatinine clearance and cystatin-C, also provide additive information on cardiovascular outcomes and bleeding. [11] [12] [13] In studies of healthy elderly subjects [14] [15] [16] [17] and in patients with congestive heart failure, 18, 19 chronic and acute coronary artery disease, [20] [21] [22] GDF-15, a marker of oxidative stress and inflammation, 15, 23, 24 provides independent prognostic information on cardiovascular events beyond cardiovascular risk factors and other biomarkers. In this pre-defined biomarker substudy within the ARISTOTLE trial we assessed the associations between GDF-15 levels at baseline and clinical outcomes including adjustments for established cardiovascular risk factors and other biomarkers in 14,798 patients with atrial fibrillation. 25 We also compared the prognostic information with that of the currently isk indicators for stroke, bleeding and mortality, in patients with atrial fibrillatio ion n.
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Methods

The ARISTOTLE Trial
The details of the ARISTOTLE trial have been published. 25 The ARISTOTLE trial enrolled 18,201 patients with atrial fibrillation and at least one CHADS 2 risk factor for stroke. Patients were randomized double blind to either warfarin (n=9,081) or apixaban 5 mg twice daily (n=9,120). The primary endpoint was stroke or systemic embolism. The median length of followup was 1.9 years for the participants in the biomarker cohort consisting of 14,798 included patients with availability to plasma samples for determination of GDF-15 and other biomarkers.
Approval by the appropriate ethics committees was obtained at all sites. All patients provided written informed consent.
Endpoints and Clinical Risk Classification
The endpoints in this study included stroke or systemic embolism; ischemic stroke and systemic embolism, hemorrhagic stroke, myocardial infarction; all-cause mortality; cardiac death (excluding bleeding and other non-cardiac causes). Bleeding was classified according to the International Society on Thrombosis and Haemostasis (ISTH) criteria with ISTH major bleeding as the primary safety endpoint. A blinded clinical events committee using pre-specified criteria centrally evaluated all outcome events. 26 Patients were classified by CHADS 2 scores 0-1, 2 or 3 and by CHA 2 DS 2 VASc scores according to 0-1, 2, 3, 4 and 5. Major bleeding outcomes were evaluated in relation to the HASBLED score classified by 0-1, 2 or 3.
Biochemical methods
All patients were required to provide plasma samples at randomization which were frozen and up was 1.9 years for the participants in the biomarker cohort consisting of 14,79 98 8 8 in in incl cl clud ud uded ed ed patients with availability to plasma samples for determination of GDF-15 and other biomarkers.
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En En ndp dp dpoi oints an an and d Cl Cl Clin nic ic ca al l R Ris is sk k Cl Cl C as as ssi si s fi fi ica a ati tio on on Th Th The e e en en endp dp dpoi oi oint nt nts s s in in in t t thi hi his s s st st stud ud udy y y in in incl cl clud ud ude e ed d d st st stro ro roke ke ke o o or r r sy sy syst st stem em emic ic ic e e emb mb mbol ol olis is ism; m; m; is is isch ch chem em emic ic ic s s str tr trok ok oke e e an an and d d sy sy syst st stem em emic ic ic 5 stored in aliquots at -70°C until analyzed centrally. The GDF-15 level was determined by the Elecsys ® GDF-15 pre-commercial assay (ROCHE Diagnostics) composed of a monoclonal mouse antibody for capture, and a monoclonal mouse antibody fragment, (F(ab´)2), for detection, and uses a sandwich assay format. Detection is based on an electrochemiluminescence immunoassay (ECLIA), using a ruthenium(II) complex label. The pre-commercial assay correlates closely with a previously established IRMA method (r=0.9801, regression
Passing/Bablok: slope 1.049, intercept -136 ng/L). 18 The assay is reported to have an inter-assay coefficient of variation of 2.3% at 100 ng/L and 1.8% at 17200 ng/L, intra-assay coefficient of variation was 0.8 % at 1100 ng/L and 0.9 % at 18600 ng/L with lower detection limit <10 ng/L.
Combining intra-and interassay variability the coefficients of variation at our laboratory was 4.4% at 1500 ng/L and 4.5% at 5900 ng/L.
The other biomarker levels were analyzed with immunoassays cTnI-hs on the ARCHITECT i1000SR (Abbott Diagnostics), the NT-proBNP level on the Cobas® Analytics e601 and c501 Immunoanalyzer (Roche Diagnostics) and Cystatin-C with the Architect system ci8200 (Abbott Laboratories, Abbott Park, IL, USA) using the particle enhanced turbidimetric immunoassay (PETIA) from Gentian (Gentian, Moss, Norway). All central biochemical analyses were performed at Uppsala Clinical Research Center (UCR) laboratory, Sweden.
Statistical Analyses
Demographics and other baseline characteristics were summarized using frequencies for Combining intra-and interassay variability the coefficients of variation at our lab ab bor r ra at a or or ory y y wa wa was s 4.4% at 1500 ng/L and 4.5% at 5900 ng/L.
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Estimates of the cumulative hazard rate were calculated and plotted. All presented event rates
were reported per 100 patient-years of follow up. All statistical tests were two-tailed and performed at the 0.05 significance level. Since the analyses were exploratory, no adjustments for multiple comparisons were made. The Statistics section at Uppsala Clinical Research Centre (UCR) conducted the statistical analyses, using SAS software, version 9.3 (SAS Institute Inc., Cary, NC, USA).
Results
Distribution of GDF-15
The GDF-15 levels were skewly distributed with median 1383 (25 th percentile 977, 75 th percentile 2052) ng/L in the total population without any differences between the randomized treatment groups. Accordingly, 60.4% had GDF-15 levels above 1200 ng/L, which is the 90% percentile of healthy subjects of similar age, and more than 32.3% had levels above 1800 ng/L considered to identify the highest risk group among patients with coronary artery disease.
Baseline characteristics in relation to GDF-15
Almost all baseline characteristics, risk scores and medications were associated to GDF-15 
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( Table 1 ). The GDF-15 level was correlated to the levels of cystatin-C, NT-pro-BNP and cTnIhs (Supplemental Figure 1) . In multivariable analyses the main independent drivers of higher GDF-15 levels were age, diabetes mellitus, cystatin-C (renal dysfunction), NT-pro-BNP and cTnI-hs (cardiac dysfunction), history of anemia and current smoking as shown in Table 2 .
Relation of GDF-15 to stroke or systemic embolism in atrial fibrillation
There were 396 events (1.40 %/year) of stroke or systemic embolism during the median followup of 1.9 years. Annual rates of stroke increased significantly with rising GDF-15 levels. In Table 2 ). The GDF-15 level and the CHA 2 DS 2 VASc score provided statistically significant independent prognostic information on mortality; the c-index was 0.637 for CHA 2 DS 2 VASc score alone and increased substantially to 0.707 (p<0.0001) when adding GDF-15. In unadjusted analysis there was also a significant association between the GDF-15 level and subsequent MI, which vanished after adjustment for baseline characteristics, risk factors and other biomarkers (Supplemental Table 1 ).
The analysis of continuous GDF-15 showed a consistent increase in hazard for total and CV death and MI throughout the range of GDF-15 (Supplemental Figure 2 -3 ).
The GDF-15 level and CHA 2 DS 2 VASc score and the other biomarkers provided statistically significant independent prognostic information on mortality; the c-index was 0.744 without and increased to 0.755 (p<0.0001) with GDF-15. This corresponded to a net reclassification improvement of 26 % by adding GDF-15. There were no interactions between GDF-15 levels and the relative reduction in mortality by apixaban as compared with warfarin, which was similar throughout the range of GDF-15 (Supplemental Table 2 
GDF-15 in relation to major bleeding
A total of 669 (2.61 %/year) major bleedings were observed in this substudy cohort. Higher GDF-15 levels were significantly associated with 3.5 times higher rate of major bleeding in the highest compared with the lowest quartile in unadjusted analyses and these associations remained stable over time (Figure 1c) . These associations remained significant even after adjusting for all base-line characteristics, established risk factors and cardiac biomarker with adjusted HR 2.00 (1.48-2.69) in the highest versus the lowest quartile of GDF-15 (Figure 2c ).
The GDF-15 level and the HASBLED score provided significant independent prognostic information on major bleeding; the c-index was 0.633 for HASBLED score alone and increased 
Discussion
The major findings of this study were that GDF-15 levels in atrial fibrillation are higher than in healthy subjects 18 but fairly similar to those in elderly community dwellers. 14 . Th Th Ther er re e e we we were re re n n no o o in in inte te t ra ra act ct ctio io ions ns ns b between with age, diabetes mellitus, renal dysfunction (Cystatin-C), myocardial dysfunction (NTproBNP, cTnI-hs), history of anemia and smoking being the main associations with a higher GDF-15 level. 14, 15, 20, 22, 24, 29, 30 In unadjusted analyses higher GDF-15 level was related to a higher risk of all cardiovascular outcomes i.e. stroke, total and cardiac mortality, myocardial infarction and major bleeding. After adjusting for all baseline-characteristics, co-morbidities and biomarkers the GDF-15 level remained an independent risk indicator for major bleeding and death. Therefore GDF-15 seems to be a biomarker improving risk stratification for bleeding and mortality beyond clinical risk factors in anticoagulated patients with atrial fibrillation.
So far only clinical risk factors are used for risk stratification of patients with atrial fibrillation concerning their risk of stroke. The CHA 2 DS 2 VASc score is currently the most commonly used risk score for stroke. 1, 3 Recently we showed that level of the biomarkers NTproBNP and cardiac troponin were able to improve the risk stratification for stroke in comparison to clinical risk factors alone. [7] [8] [9] [10] In addition these biomarkers also provided prognostication of mortality beyond clinical risk factors. In the present study the measurement of GDF-15, like NT-proBNP and cardiac troponin, appeared as a risk indicator for stroke and mortality beyond clinical characteristics and clinical risk scores. However, these three biomarkers partly reflect the same processes, i.e. myocardial dysfunction and cardiovascular comorbidity. Therefore, in multivariable analysis GDF-15 did not appear as an independent risk indicator for stroke in the presence of both the other biomarkers and clinical characteristics.
However, even in the presence of the other biomarkers and clinical characteristics GDF-15 provided additional information on the risk of death, which might be useful if included in future risk stratification strategies.
Recommending anticoagulant treatment in patients with atrial fibrillation is based on fibrillation concerning their risk of stroke. The CHA 2 DS 2 VASc score is currentl ly y y th th he mo mo most st st commonly used risk score for stroke. 1, 3 Recently we showed that level of the biomarkers NTpr roB oB BNP NP NP a a and nd nd c car rdi di dia ac ac troponin were able to improv ov ove e the risk stratif if fic i i at tio io on n n fo f r stroke in co om mp mparison to o cl cl clin n nic cal al al ris is isk k k fa fa act ct ctor ors s s a al alon on ne e. . The identification of GDF-15 as a biomarker independently related to major bleeding might both lead to improved risk stratification and a better understanding of the underlying causes of bleeding during anticoagulant treatment. GDF-15 is a divergent member of the transforming growth factor family which can be secreted from a broad range of cells, e.g. cytokine secreted from adipocytes and myocytes in response to, and maybe protecting from, stress such as cellular ischemia, mechanical and oxidative stress. 32, 33 Plasma levels of GDF-15 are increased in response to inflammation and may also be involved in maintaining the inflammatory activity. the GDF-15 and bleeding in the present trial was seen in relation to major and clinically relevant bleeding and also trended in the same direction for hemorrhagic stroke. The cause of the association between GDF-15 and the risk of bleeding might be that GDF-15 is increased at cellular stress and cellular vulnerability, which might be associated with a raised risk of bleeding at different kinds of tissue damage. There is also a potential for a specific mechanism as GDF-15
has an inhibitory effect on platelet activation mediated via a mechanism similar to glycoprotein IIb/IIIa inhibition resulting in a lower ability to form thrombus.
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Limitations
These data come from a population with atrial fibrillation and at least one risk factor for stroke included in a clinical trial and may therefore not be immediately generalized to the total atrial process, which currently might only be detected by the GDF-15 elevation. The in in nde de epe pend nd nden en ent t t association between GDF-15 and the risk of bleeding confirmed our recent publication of the a ame me me r r rel el elat at atio io ion n nshi ip p p i in in patients treated with dual an an nt ti t p p platelet treatme me ent n a aft ft fter er er acute coronary y ynd nd drome in th the e PL L LAT AT ATO O O tr tr tria ia ial l l ( (a (abs bs str tr rac act t E E ESC C co ong gr re ess 20 20 2013 13) ). T The he e i ind ndep ep pen nde de ent nt nt r rel el lat at a io io ion n be e et tw twee ee een n h he e e GD GD GDF-F-15 15 5 a and nd bl le leed ed din n ng g g in in t t the he e p p pre re rese sen nt nt t t tri ri rial al al w w was as a s se ee en n n in n n r r rel e elat at tio io ion n n to to o m m ma a ajo or or a and nd nd c cli lini ni nic c call ll ly re rele le eva a ant n bleeding and d a a als ls so o tr tr tren en ende de ded in in in t t the he e s s sam am ame e di di dire re rec c cti ti t on on on f f for or or h h hem em mor or o rh rh rhag ag agic ic ic s str r rok ok oke. e. e. T T The he he c cau au ause se se o o of f f th t e 14 fibrillation population. The results concerning relations to clinical characteristics, other biomarkers and outcome events are in accordance with those in other patient populations but should preferably also be verified in other cohorts with atrial fibrillation.
Conclusions
In patients with atrial fibrillation GDF-15 is a risk factor for major bleeding, death and stroke in <0 <0 <0.00 *The geometric means are calculated by the antilogs of the model-adjusted means of the natural log transformed GDF-15. The geometric means by baseline characteristic category and ratios of geometric means are estimated in a model including only baseline characteristics. The geometric means for each baseline biomarker quartile group are estimated in models including baseline characteristics and the specific biomarker. Baseline characteristics also included in the model but not shown: BMI, Heart rate, Bleeding history, Region, Baseline statin treatment, type of AF, prior VKA use. **The ratio of geometric means is estimated in a model including baseline characteristics and all three biomarkers. Table I  2   Supplemental Table II Supplemental Figure III  9 artery bypass graft/percutaneous coronary intervention; treatment at randomization with aspirin, angiotensin-converting enzyme inhibitors or angiotensin receptor blocker; and use of amiodarone. For the major bleeding endpoint: history of anemia; chronic liver disease; hematocrit; use of nonsteroidal anti-inflammatory drug and history of spontaneous or clinical relevant bleeding were also included. §Model 3 also adjusted for biomarker levels (cystatin-C, cTnI-hs and NT-proBNP).
Figure Ia. NT-proBNP
NT-proBNP, N-terminal brain natriuretic peptide; GDF-15, growth differentiation factor 15
Supplemental Figure III . Rate of stroke and systemic embolism in relation to plasma GDF-15 levels modeled using restricted cubic regression spline.
GDF-15, growth differentiation factor 15
